[Specific features of diphtheria vaccinal process in children with rheumatic diseases].
Clinical and immunological examination of 55 children aged 6-15 years with rheumatic diseases, immunized against diphtheria, was carried out. All children were immunized at the stage of clinical and laboratory remission and in some cases while undergoing a prolonged course of cytostatic therapy or therapy with nonsteroid anti-inflammatory remedies. This examination demonstrated that in the overwhelming majority of children with rheumatic diseases the diphtheria vaccinal process took an asymptomatic course and had no influence on the course of the main disease. Specific features, characteristic of the immune status of this group of children, were established. In the course of the vaccinal process the restoration of the initially inhibited characteristics (the production of TNF-alpha and IL-2) to normal values were shown to occur, which was indicative of the fact that the reserve capacities of immunocompetent cells were retained in these patients. This study also revealed that immunization of children with rheumatic diseases with adsorbed DT and D toxoids with reduced antigen content was not excessive antigenic stimulation for such children, as it did not lead to immunopathological shifts, but induced transient phase changes in immunological characteristics, similar to those in healthy children. Protective levels of antibodies to diphtheria were shown to retain for a long time with considerable prolongation of intervals between booster injections. The simultaneous course of immunosuppressive maintenance therapy in the average dosage used for the corresponding age group did not inhibit the production of protective antibodies.
Koshcheeva
Iu V
IuV
Research Institute of Child Infections, Russian Center of Emergency and Radiation Medicine, St. Petersburg, Russia.
Kharit
S M
SM
Kalinina
N M
NM
D000293:Adolescent; D000907:Antibodies, Bacterial / Q000097:blood*; D002648:Child; D003353:Corynebacterium diphtheriae / Q000276:immunology*; D004165:Diphtheria / Q000276:immunology* / Q000517:prevention & control; D004168:Diphtheria Toxoid / Q000008:administration & dosage; D022422:Diphtheria-Tetanus Vaccine / Q000008:administration & dosage; D006801:Humans; D007376:Interleukin-2 / Q000032:analysis; D012075:Remission, Spontaneous; D012216:Rheumatic Diseases / Q000097:blood / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis; D014611:Vaccination
D000907:Antibodies, Bacterial; D004168:Diphtheria Toxoid; D022422:Diphtheria-Tetanus Vaccine; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha